NCT02525198 · COMPLETED
The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial
This trial is testing a dietary supplement that combines fatty acids (like omega-3s) and flavonoids (plant-based compounds) to see whether the combination improves cognition in older adults with mild cognitive impairment or subjective memory complaints. It is a Phase NA trial, meaning it is a straightforward intervention study rather than a staged drug approval process. Researchers want to know if these two compound types work better together than either would alone.
You may qualify if
- Male and female, aged ≥ 55 years
- Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression
- Willing and able to provide written informed consent.
- Understands and is willing and able to comply with all study procedures.
- Fluent in written and spoken English.
- In good general health including blood biochemical, haematological and urinalysis within the normal range at screening (as judged by the clinical advisor)
- Normal, or corrected to normal vision and hearing
- Right handed, for MRI
- Stable use of any prescribed medication for at least four weeks
You're excluded if
- Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder
- Parent or sibling who developed premature dementia \<60y (suggestive of a familial monogenic form of cognitive decline)
- Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness > 24 hours
- History of alcohol or drug dependency within the last 2 years
- Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
- Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
- Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
- Carotid stents or severe stenosis
- Known allergy to fish or any other component in the intervention supplements
- Existing medical conditions likely to affect the study measures (as judged by clinical adviser)
- Uncontrolled hypertension (Systolic Blood Pressure (SBP) >140mmHg, Diastolic Blood Pressure (DBP) >90mmHg)
- BMI >40kg/m2
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-05-14